Trial Profile
A Multi-Center, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Study to Determine the Safety of PEP005 [ingenol mebutate] 0.0025%, 0.01% and 0.05% Gel With Two Treatment Schedules, Day 1 & 2 or Day 1 & 8 Applications to Nodular Basal Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Feb 2015
Price :
$35
*
At a glance
- Drugs Ingenol mebutate (Primary)
- Indications Basal cell cancer; Skin cancer
- Focus Adverse reactions
- Sponsors Peplin
- 23 Aug 2007 The expected completion date for this trial is now 1 May 2006.
- 18 Jul 2006 Status change
- 06 Sep 2005 New trial record.